



04-30-07

Attorney's Docket No.: 18202-017001 / 1081

COJC  
AJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lin Zhi et al.  
Patent No. : 7,026,484  
Issue Date : April 11, 2006  
Serial No. : 10/080,926  
Filed : February 22, 2002  
Title : **TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS  
AND METHODS**

Art Unit : 1625  
Examiner : D. Margaret Seaman  
Conf. No. : 7786  
Cust. No. : 20985

**Attn.: Certificate of Corrections Branch**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Dear Sir:

Transmitted herewith are a Request for a Corrected Certificate of Correction (3 pages), Hand-Annotated Sheets (5 pages), and a return postcard for filing in connection with the above-identified application. All errors sought to be corrected were made in printing by the Patent and Trademark Office, and no fee is believed to be due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:

☒ The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 18202-017001 / 1081  
**Address all correspondence to:**  
Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-4777  
Facsimile: (202) 626-7796  
email: seidman@fr.com

**Certificate  
MAY 02 2007  
of Correction**

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**  
"Express Mail" Mailing Label Number EV 740126428 US  
Date of Deposit April 27, 2007  
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lin Zhi *et al.*  
Patent No. : 7,026,484  
Issue Date : April 11, 2006  
Serial No. : 10/080,926  
Filed : February 22, 2002  
Title : **TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS  
AND METHODS**

Art Unit : 1625  
Examiner : D. Margaret Seaman  
Conf. No. : 7786  
Cust. No. : 20985

**Attn.: Certificate of Corrections Branch**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR CORRECTION TO ISSUED**  
**CERTIFICATE OF CORRECTION**

Dear Sir:

Patentee respectfully requests that a corrected Certificate of Correction be issued for the above referenced patent. New errors were introduced by the PTO in the Certificate of Correction issued on February 27, 2007. A hand-corrected version of the issued Certificate of Correction for the above captioned patent is attached. Patentee respectfully requests correction of the following errors introduced by the PTO:

In Claim 32, on page 8 of the issued Certificate of Correction, in lines 21-22 the PTO incorrectly printed "4-methyl" instead of -4-trifluoromethyl-. Please replace "4-methyl" with -4-trifluoromethyl- as originally recited in the Request for Certificate of Correction mailed on August 9, 2006. Further basis for this correction is found on page 122, lines 3-4 of the originally filed application.

In Claim 32, on page 9 of the issued Certificate of Correction, in lines 7-8 the PTO incorrectly printed "4-4trifluorometyl" instead of -4-trifluoromethyl-. Please replace "4-4trifluorometyl" with -4-trifluoromethyl- as originally recited in the Request for Certificate of Correction mailed on August 9, 2006. Further basis for this correction is found on page 123, lines 4-5 of the originally filed application.

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

"Express Mail" Mailing Label Number EV 740126428 US

Date of Deposit: April 27, 2007

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman

Applicant : Lin Zhi et al.  
Patent No. : 7,026,484  
Issued : April 11, 2006  
Serial No. : 10/080,926  
Filed : February 22, 2002

Attorney's Docket No.: 18202-017001 / 1081  
**Request for Corrected Certificate of Correction**

In Claim 33, on page 10 of the issued Certificate of Correction, in lines 29-30 the PTO incorrectly printed "pentanoo" instead of -pentao-. Please replace "pentanoo" with -pentao- as originally recited in the Request for Certificate of Correction mailed on August 9, 2006. Further basis for this correction is found on page 127, lines 1-2 of the originally filed application.

In Claim 33, on page 10 of the issued Certificate of Correction, in lines 31-32 the PTO incorrectly printed "cyclohexan" instead of -cyclohexano-. Please replace "cyclohexan" with -cyclohexano- as originally recited in the Request for Certificate of Correction mailed on August 9, 2006. Further basis for this correction is found on page 127, lines 3-4 of the originally filed application.

In Claim 33, on page 11 of the issued Certificate of Correction, in lines 15-16 the PTO incorrectly omitted an open bracket, [ , immediately preceding the letter 'g'. The PTO also incorrectly omitted the word -and- immediately following the semicolon. Please insert an open bracket, [ , immediately preceding the letter 'g' and insert the word -and- immediately following the semicolon as originally recited in the Request for Certificate of Correction mailed on August 9, 2006. Further basis for these corrections are found on page 20, lines 13-14 of the Amendment and Response, mailed on June 21, 2004.


In Claim 53, on page 15 of the issued Certificate of Correction, in line 13 the PTO incorrectly omitted the word -or- immediately following the semicolon. Please insert the word -or- immediately following the semicolon as originally recited in the Request for Certificate of Correction mailed on August 9, 2006. Further basis for this correction is found on page 19, line 20 of the Preliminary Amendment and Request for Continued Examination, mailed on January 21, 2005.

Applicant : Lin Zhi et al.  
Patent No. : 7,026,484  
Issued : April 11, 2006  
Serial No. : 10/080,926  
Filed : February 22, 2002

Attorney's Docket No.: 18202-017001 / 1081  
**Request for Corrected Certificate of Correction**

Patentee respectfully requests correction of these errors. All errors sought to be corrected were made in printing by the Patent and Trademark Office, and no fee is believed to be due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050.

Respectfully submitted,



---

Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 18202-017001 / 1081

**Address all correspondence to:**

Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-4777  
Facsimile: (202) 626-7796  
email: seidman@fr.com

10730583.doc

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 8 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2-methylpropyl)-4-trifluoromethylcyclopentano[g]-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2,2,2-chlorodifluoro-ethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,7a(cis),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethylcyclopentano[g]-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,7a(cis),8-Hexahydro-8-(2,2-dimethoxyethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,8,8a(cis)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9H-cyclohexano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-4c,5,6,7,8,9,9a(cis),10-Octahydro-10-(2,2,2-trifluoroethyl)-4-trifluoromethylcycloheptano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-cis-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-cis-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-cis-Dihydro-5-(4-nitrophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-cis-Dihydro-5-(4-dimethylaminophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-cis-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one; ~~4-trifluoromethyl~~
- (±)-5,6-cis-Dihydro-5-(3-trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-cis-Dihydro-5-(4-fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-Dihydro-5-phenyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo-3,2-f]quinolin-2(1H)-one;
- (±)-5,6-cis-Dihydro-5-(4-methoxyphenyl)-6-methyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-cis-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2-dimethoxyethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-cis-Dihydro-5-isopropyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;
- (±)-5,6-Dihydro-5-(2-ethoxycarbonyl-ethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 9 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5,6,7,8-Tetrahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano[g]-pyrrolo[3,2-f]quinolin-2(1H)-one;  
8-Trifluoroethyl-4-trifluoromethyl-6,8-dihydrocyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;  
9-Trifluoroethyl-trifluoromethyl-9H-benzo[g]pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-(3-Trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-(4-Fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-(2-Ethoxycarbonyl-ethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Methyl-6-(1-hydroxyethyl)-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Methyl-6-acetyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Formyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Acetyloxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
2-Acetyloxy-5-hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinoline;  
6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
5-Ethoxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
(+)-6-(1-Methoxyethyl)-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;  
7-Allyl-6-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2(1H)-one;  
6-Ethyl-7-methyl-4-trifluoromethyl-5H-pyrrolo[2,3-f]quinolin-2(1H)-one;

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 10 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

7-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;  
7-(2-Hydroxyethyl)-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;  
(+)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethyl-cyclopentano-[*g*]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(-)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano-[*g*]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-Dihydro-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-Dihydro-7-ethyl-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
5-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
6-Formyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one; and  
5,6-Dimethyl-7-(2,2-difluorovinyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one.

33. A compound according to claim 1, wherein said compound is selected from the group consisting of:

(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano-[*g*]pyrrolo-[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-Dihydro-5,6-*cis*-dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-chlorodifluoroethyl)-4-trifluoromethylcyclopentano-[*g*]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
*pentano* (±)-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethylcyclopentano-[*g*]-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
*cyclohexano* (±)-4*c*,5,6,7,8,8*a*(*cis*)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9*H*-cyclohexano-~~eyetohexan~~[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-*cis*-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-*cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
(±)-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**


PATENT NO. : 7,026,484 B2  
 APPLICATION NO. : 10/080926  
 DATED : April 11, 2006  
 INVENTOR(S) : Lin Zhi et al.

Page 11 of 16


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-5,6-*cis*-Dihydro-5-methyl-6-ethyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]-quinolin-2(1*H*)-one;  
 5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 5,6,7,8-Tetrahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
 (+)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano-<sup>[3]</sup>*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one; and  
 (-)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2,2,2-trifluoroethyl)-4-trifluoromethylcyclopentano-*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one.


34. A pharmaceutical composition, comprising:  
 a pharmaceutically acceptable carrier; and  
 a compound of formula:




OR



OR



OR





UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,026,484 B2  
APPLICATION NO. : 10/080926  
DATED : April 11, 2006  
INVENTOR(S) : Lin Zhi et al.

Page 15 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R<sup>6</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups are optionally substituted;

R<sup>7</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

R<sup>8</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups are optionally substituted; or

R<sup>3</sup> and R<sup>5</sup> taken together form a bond; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>4</sup> and R<sup>6</sup> taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted; or

R<sup>6</sup> and R<sup>8</sup> taken together form a three- to eight-membered saturated or unsaturated carbocyclic ring, wherein the carbocyclic ring is optionally substituted;

R<sup>9</sup> and R<sup>10</sup> each independently is selected from among hydrogen, F, Cl, Br, I, CN, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>m</sub>(R<sup>12</sup>)<sub>2m</sub>OR<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups are optionally substituted;

R<sup>11</sup> is selected from among F, Br, Cl, I, CN, OR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup> and SR<sup>14</sup>;

R<sup>12</sup> and R<sup>13</sup> each independently is selected from among hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups are optionally substituted;

R<sup>14</sup> is selected from among hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, aryl, heteroaryl, C(O)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup> and C(O)NR<sup>15</sup>R<sup>16</sup>, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups are optionally substituted;

R<sup>15</sup> and R<sup>16</sup> each independently is selected from among hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl and C<sub>1</sub>-C<sub>8</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups are optionally substituted;

W is O or S;

X is N {R<sup>14</sup>};

Y is selected from among O, S, N {R<sup>12</sup>} and NO {R<sup>12</sup>};

Z is N {R<sup>12</sup>};

n is 0; and

m is 0 or 1;

or a pharmaceutically acceptable salt thereof.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lin Zhi et al.  
Patent No. : 7,026,484  
Issue Date : April 11, 2006  
Serial No. : 10/080,926  
Filed : February 22, 2002  
Title : **TRICYCLIC ANDROGEN RECEPTOR MODULATOR COMPOUNDS  
AND METHODS**

Art Unit : 1625  
Examiner : D. Margaret Seaman  
Conf. No. : 7786  
Cust. No. : 20985

**Attn.: Certificate of Corrections Branch**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**TRANSMITTAL LETTER**

Dear Sir:

Transmitted herewith are a Request for a Corrected Certificate of Correction (3 pages), Hand-Annotated Sheets (5 pages), and a return postcard for filing in connection with the above-identified application. All errors sought to be corrected were made in printing by the Patent and Trademark Office, and no fee is believed to be due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:

☒ The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

  
\_\_\_\_\_  
Stephanie Seidman  
Reg. No. 33,779


Attorney Docket No. 18202-017001 / 1081  
**Address all correspondence to:**  
Stephanie Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-4777  
Facsimile: (202) 626-7796  
email: seidman@fr.com

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

"Express Mail" Mailing Label Number EV 740126428 US

Date of Deposit **April 27, 2007**

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

  
\_\_\_\_\_  
Stephanie Seidman